ANDA 217634, held by Strides Pharma. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 217634 (Atorvastatin Calcium), held by Strides Pharma, was first approved by FDA on Dec 21, 2023, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2023 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Sep 30, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 21, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters